Close

Amgen (AMGN), UCB Announce FRAME Phase 3 Met co-Primary Endpoints; One Secondary Endpoint Missed

February 22, 2016 6:21 AM EST Send to a Friend
Amgen (Nasdaq: AMGN) and UCB announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login